Reunion Neuroscience is developing RE104, a patented prodrug of 4-OH-DiPT that targets the serotonin 2A receptor to provide fast-acting, short-duration therapeutic effects for postpartum depression and other mental health disorders. The company aims to deliver effective treatment options for patients whose needs are unmet by current antidepressant therapies.
Funding
$103M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
NHFounders
Product
Problem
Current antidepressant therapies do not adequately address the needs of all patients with postpartum depression (PPD) and other mental health disorders, often exhibiting delayed onset of action or limited efficacy. There is a need for fast-acting, short-duration treatments that can provide rapid relief and improved outcomes for these underserved populations.
Solution
Reunion Neuroscience is developing serotonergic psychedelic therapeutics, including RE104, a patented prodrug of 4-OH-DiPT, for the treatment of postpartum depression (PPD) and adjustment disorder (AjD). RE104 is designed to target the serotonin 2A receptor (5HT2AR) to provide fast-acting, short-duration therapeutic effects. The company's approach builds upon decades of psychedelic research, aiming to create safer therapeutics that provide durable antidepressive effects. Reunion Neuroscience is also developing RE245, a discovery-stage, non-psychedelic asset, for application in chronic treatment paradigms and indications, designed to have selective potency at the target serotonin 2A receptor (5HT2A), without off-target 5HT2B receptor agonism.
Target Audience
The primary target audience includes individuals suffering from postpartum depression (PPD), adjustment disorder (AjD), and other underserved mental health disorders, as well as the healthcare providers who treat them.
Features
- RE104: A patented, clinical-stage prodrug of 4-OH-DiPT, a psilocybin-like compound.
- RE104 targets the serotonin 2A receptor (5HT2AR), the recognized target for the antidepressant effects of psychedelic compounds.
- RE104 is under evaluation in the RECONNECT Phase 2 clinical trial as a potential treatment for PPD.
- RE104 is under evaluation in the planned REKINDLE Phase 2 clinical trial as a potential treatment for AjD in cancer and other medical illnesses.
- RE245: A discovery-stage, non-psychedelic asset, for application in chronic treatment paradigms and indications.
- RE245 is structurally similar to classic psychedelics and is designed to have selective potency at the target serotonin 2A receptor (5HT2A), without off-target 5HT2B receptor agonism.